tubastatin A [Ligand Id: 9702] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL2018302 (Tubastatin A) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| histone deacetylase 1/Histone deacetylase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL325] [GtoPdb: 2658] [UniProtKB: Q13547] | ||||||||
| ChEMBL | Inhibition of human HDAC1 | B | 5.42 | pKi | 3823.3 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of human recombinant HDAC1 using RHKKAc peptide as substrate incubated for 5 to mins prior to substrate addition measured after 2 hrs | B | 4.79 | pIC50 | 16400 | nM | IC50 | J Med Chem (2012) 55: 639-651 [PMID:22165909] |
| ChEMBL | Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate | B | 4.79 | pIC50 | 16400 | nM | IC50 | J Med Chem (2012) 55: 9891-9899 [PMID:23009203] |
| ChEMBL | Inhibition of human recombinant HDAC1 protein using RHKKAc from p53 as substrate | B | 4.79 | pIC50 | 16400 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate | B | 4.79 | pIC50 | 16400 | nM | IC50 | J Med Chem (2013) 56: 6775-6791 [PMID:23905680] |
| ChEMBL | Inhibition of human recombinant HDAC1 using RHKKAc as substrate | B | 4.79 | pIC50 | 16400 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length GST-tagged human HDAC1 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 4.79 | pIC50 | 16400 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC1 (unknown origin) | B | 4.79 | pIC50 | 16400 | nM | IC50 | Eur J Med Chem (2015) 96: 340-359 [PMID:25899338] |
| ChEMBL | Inhibition of HDAC1 (unknown origin) | B | 4.79 | pIC50 | 16400 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Inhibition of human recombinant full-length HDAC1 (1 to 482 residues) expressed in baculovirus using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.79 | pIC50 | 16400 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of HADC1 (unknown origin) | B | 4.79 | pIC50 | 16400 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of recombinant human HDAC1 using RHKKAc fluorogenic peptide substrate | B | 4.79 | pIC50 | 16400 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of human HDAC1 using p53 fluorogenic peptide (379 to 382 residues) RHKKAc as substrate by fluorescence-based assay | B | 4.79 | pIC50 | 16400 | nM | IC50 | Eur J Med Chem (2018) 143: 1406-1418 [PMID:29133060] |
| ChEMBL | Inhibition of HDAC1 (unknown origin) | B | 4.79 | pIC50 | 16400 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of recombinant human HDAC1 using Fluor de Lys-SIRT1 as substrate incubated for 15 mins by fluorescence assay | B | 4.84 | pIC50 | 14350 | nM | IC50 | Eur J Med Chem (2016) 116: 126-135 [PMID:27060764] |
| GtoPdb | - | - | 4.86 | pIC50 | 13800 | nM | IC50 | US8748451. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.86 | pIC50 | 13800 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 expressed in Sf21 cells using RHKK(Ac) as substrate after 60 mins by fluorimetric method | B | 5 | pIC50 | >10000 | nM | IC50 | Eur J Med Chem (2017) 127: 115-127 [PMID:28038324] |
| ChEMBL | Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay | B | 5 | pIC50 | >10000 | nM | IC50 | Bioorg Med Chem (2020) 28: 115250-115250 [PMID:31924504] |
| ChEMBL | Inhibition of HDAC1 (unknown origin) | B | 5.09 | pIC50 | 8100 | nM | IC50 | J Med Chem (2020) 63: 10246-10262 [PMID:32815366] |
| ChEMBL | Inhibition of human full length recombinant HDAC1 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 5.1 | pIC50 | 8000 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | Inhibition of HDAC1 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for incubated for 1 hrs by fluorescence microtiter plate reader assay | B | 5.12 | pIC50 | 7582.5 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of recombinant human HDAC1 using Z-(Ac)-Lys-AMC as substrate incubated for 40 mins by fluorescence based assay | B | 5.15 | pIC50 | 7048 | nM | IC50 | Eur J Med Chem (2021) 218: 113392-113392 [PMID:33831778] |
| ChEMBL | Inhibition of HDAC1 (unknown origin) measured after 30 mins by fluorescence microplate reader assay | B | 5.3 | pIC50 | >5000 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | Inhibition of recombinant human KDAC1 using acetylated p53 (379 to 382 residues) as substrate by fluorescence assay | B | 5.54 | pIC50 | 2870 | nM | IC50 | J Med Chem (2016) 59: 1613-1633 [PMID:26681404] |
| ChEMBL | Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA | B | 5.57 | pIC50 | 2700 | nM | IC50 | ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317] |
| ChEMBL | Inhibition of HDAC1 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method | B | 5.57 | pIC50 | 2700 | nM | IC50 | Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330] |
| ChEMBL | Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay | B | 5.6 | pIC50 | 2490 | nM | IC50 | Medchemcomm (2019) 10: 1109-1115 [PMID:31391882] |
| ChEMBL | Inhibition of human recombinant HDAC1 using ZMAL (Z-Lys(Ac)-AMC) fluorogenic substrate incubated for 90 mins by fluorescence based assay | B | 5.6 | pIC50 | 2490 | nM | IC50 | J Med Chem (2020) 63: 10339-10351 [PMID:32803970] |
| ChEMBL | Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis | B | 5.7 | pIC50 | >2000 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925] |
| ChEMBL | Inhibition of recombinant C-terminal His/FLAG-tagged human HDAC1 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay | B | 5.72 | pIC50 | 1910 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of full length C-terminal His/FLAG-tagged human HDAC1 expressed in baculovirus expression system using ZMAL as substrate incubated for 90 mins by fluorescence assay | B | 5.72 | pIC50 | 1910 | nM | IC50 | ACS Med Chem Lett (2020) 11: 2268-2276 [PMID:33214839] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.85 | pIC50 | 1400 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis | B | 5.95 | pIC50 | 1109.7 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925] |
| ChEMBL | Inhibition of human HDAC1 pre-incubated for 5 mins before substrate addition and measured after 30 mins by fluorescence based assay | B | 6.12 | pIC50 | 752 | nM | IC50 | J Med Chem (2021) 64: 1116-1126 [PMID:33356256] |
| ChEMBL | Inhibition of HDAC1 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 6.84 | pIC50 | 144 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
| histone deacetylase 1/Histone deacetylase 1 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4001] [GtoPdb: 2658] [UniProtKB: O09106] | ||||||||
| ChEMBL | Inhibition of HDAC1 in mouse N2A cells | B | 5.09 | pIC50 | 8100 | nM | IC50 | ACS Med Chem Lett (2020) 11: 706-712 [PMID:32435374] |
| histone deacetylase 10/Histone deacetylase 10 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5103] [GtoPdb: 2614] [UniProtKB: Q969S8] | ||||||||
| ChEMBL | Inhibition of HDAC10 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6775-6791 [PMID:23905680] |
| ChEMBL | Inhibition of human recombinant HDAC10 using RHKKAc as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of N-terminal GST-tagged human HDAC10 (1 to 481 residues) using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of HDAC10 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Inhibition of HDAC10 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of human recombinant HDAC10 protein using RHKKAc from p53 as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human full length recombinant HDAC10 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 4.6 | pIC50 | 25000 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.43 | pIC50 | 3710 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of tubastatin-Alexa647-tracer binding to recombinant GST-tagged HDAC10 (unknown origin) measured after 1 hr by TR-FRET assay | B | 7.9 | pIC50 | 12.59 | nM | IC50 | J Med Chem (2019) 62: 4426-4443 [PMID:30964290] |
| ChEMBL | Inhibition of dye-labeled tracer binding to HDAC10 (unknown origin) transfected in human HeLa cells measured after 2 hrs by nano-luciferase reporter gene-based BRET assay | B | 7.9 | pIC50 | 12.59 | nM | IC50 | J Med Chem (2019) 62: 4426-4443 [PMID:30964290] |
| histone deacetylase 11/Histone deacetylase 11 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3310] [GtoPdb: 2615] [UniProtKB: Q96DB2] | ||||||||
| ChEMBL | Inhibition of HDAC11 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6775-6791 [PMID:23905680] |
| ChEMBL | Inhibition of human recombinant HDAC11 using RHKKAc as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length N-terminal GST-tagged human HDAC11 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of human recombinant HDAC11 protein using RHKKAc from p53 as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of HDAC11 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Inhibition of HDAC11 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of human full length recombinant HDAC11 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 4.8 | pIC50 | 16000 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | Inhibition of recombinant human HDAC11 measured after 30 mins by fluorescence microplate reader assay | B | 5.3 | pIC50 | >5000 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.42 | pIC50 | 3790 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| histone deacetylase 2/Histone deacetylase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1937] [GtoPdb: 2616] [UniProtKB: Q92769] | ||||||||
| ChEMBL | Inhibition of C-terminal GST-tagged recombinant human HDAC2 (1 to 488 residues) expressed in Baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins measured after 15 mins by microplate reader based fluorescence assay | B | 5.24 | pKi | 5770 | nM | Ki | Bioorg Med Chem (2019) 27: 115036-115036 [PMID:31431326] |
| ChEMBL | Inhibition of human recombinant full-length C-terminal GST-tagged HDAC2 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of human recombinant HDAC2 protein using RHKKAc from p53 as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6775-6791 [PMID:23905680] |
| ChEMBL | Inhibition of human recombinant HDAC2 using RHKKAc as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length C-terminal 6x-His tagged human HDAC2 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of HDAC2 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of human HDAC2 using p53 fluorogenic peptide (379 to 382 residues) RHKKAc as substrate by fluorescence-based assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2018) 143: 1406-1418 [PMID:29133060] |
| ChEMBL | Inhibition of HADC2 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of HDAC2 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Inhibition of human full length recombinant HDAC2 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 4.72 | pIC50 | 19000 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | Inhibition of full length human recombinant C-terminal GST-tagged HDAC2 expressed in insect cells using RHKK(Ac) as substrate after 60 mins by fluorimetric method | B | 5 | pIC50 | >10000 | nM | IC50 | Eur J Med Chem (2017) 127: 115-127 [PMID:28038324] |
| ChEMBL | Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay | B | 5 | pIC50 | >10000 | nM | IC50 | Bioorg Med Chem (2020) 28: 115250-115250 [PMID:31924504] |
| ChEMBL | Inhibition of HDAC2 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for incubated for 1 hrs by fluorescence microtiter plate reader assay | B | 5.06 | pIC50 | 8674.5 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.2 | pIC50 | 6270 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of HDAC2 (unknown origin) measured after 30 mins by fluorescence microplate reader assay | B | 5.3 | pIC50 | >5000 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | Inhibition of HDAC2 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method | B | 5.41 | pIC50 | 3900 | nM | IC50 | Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330] |
| ChEMBL | Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA | B | 5.41 | pIC50 | 3900 | nM | IC50 | ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317] |
| ChEMBL | Inhibition of HDAC2 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 6.44 | pIC50 | 360 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
| histone deacetylase 3/Histone deacetylase 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1829] [GtoPdb: 2617] [UniProtKB: O15379] | ||||||||
| ChEMBL | Inhibition of HDAC3 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of full length C-terminal 6x-His tagged human HDAC3 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of HDAC3 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Inhibition of human recombinant full-length C-terminal GST-tagged HDAC3 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of HADC3 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA | B | 5.54 | pIC50 | 2900 | nM | IC50 | ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317] |
| ChEMBL | Inhibition of HDAC3 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method | B | 5.54 | pIC50 | 2900 | nM | IC50 | Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330] |
| ChEMBL | Inhibition of HDAC3 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 6.81 | pIC50 | 155 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
| histone deacetylase 3/Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL2111363] [GtoPdb: 2617] [UniProtKB: O15379, Q9Y618] | ||||||||
| ChEMBL | Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc from p53 as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of human full length recombinant HDAC3/ NcoR2 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 5.1 | pIC50 | 8000 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | Inhibition of C-terminal His-tagged recombinant human HDAC3 (1 to 428 residues)/N-terminal GST-tagged recombinant human NCoR2 (395 to 489 residues) co-expressed in baculovirus infected Sf9 cells measured after 30 mins by fluorescence microplate reader assay | B | 5.3 | pIC50 | >5000 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.9 | pIC50 | 1270 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of recombinant human KDAC3/NcoR2 using acetylated p53 (379 to 382 residues) as substrate by fluorescence assay | B | 6.11 | pIC50 | 770 | nM | IC50 | J Med Chem (2016) 59: 1613-1633 [PMID:26681404] |
| histone deacetylase 4/Histone deacetylase 4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3524] [GtoPdb: 2659] [UniProtKB: P56524] | ||||||||
| ChEMBL | Inhibition of C-terminal His-tagged/N-terminal GST-tagged recombinant human HDAC4 (627 to 1084 residues) expressed in Baculovirus infected insect cells using Boc-Lys(TFa)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins measured after 15 mins by microplate reader based fluorescence assay | B | 5.27 | pKi | 5380 | nM | Ki | Bioorg Med Chem (2019) 27: 115036-115036 [PMID:31431326] |
| ChEMBL | Inhibition of HDAC4 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of human recombinant HDAC4 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC4 using acetyl-Lys(trifluoroacetyl)-AMC as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of N-terminal GST-tagged human HDAC4 (627 to 1085 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of HDAC4 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of HDAC4 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.76 | pIC50 | 17300 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of HDAC4 (unknown origin) measured after 30 mins by fluorescence microplate reader assay | B | 5.3 | pIC50 | >5000 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | Inhibition of human full length recombinant HDAC4 using p53 (379 to 382 residues) Ac-LGK(TFA)-AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 5.52 | pIC50 | 3000 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | Inhibition of HDAC4 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 5.96 | pIC50 | 1100 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
| histone deacetylase 5/Histone deacetylase 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2563] [GtoPdb: 2660] [UniProtKB: Q9UQL6] | ||||||||
| ChEMBL | Inhibition of HDAC5 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of human recombinant HDAC5 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC5 using acetyl-Lys(trifluoroacetyl)-AMC as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of C-terminal 6x-His tagged human HDAC5 (657 to 1123 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of HDAC5 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of HDAC5 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Inhibition of HDAC5 (unknown origin) measured after 30 mins by fluorescence microplate reader assay | B | 5.3 | pIC50 | >5000 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.47 | pIC50 | 3350 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of HDAC5 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 5.64 | pIC50 | 2300 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
| ChEMBL | Inhibition of human full length recombinant HDAC5 using p53 (379 to 382 residues) Ac-LGK(TFA)-AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 6 | pIC50 | 1000 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| histone deacetylase 6/Histone deacetylase 6 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1865] [GtoPdb: 2618] [UniProtKB: Q9UBN7] | ||||||||
| ChEMBL | Inhibition of N-terminal GST-tagged recombinant human HDAC6 (1 to 1215 residues) expressed in Baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins measured after 15 mins by microplate reader based fluorescence assay | B | 8 | pKi | 10 | nM | Ki | Bioorg Med Chem (2019) 27: 115036-115036 [PMID:31431326] |
| ChEMBL | Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus-infected Sf9 insect cells using RHKK(Ac)AMC as substrate after 90 mins by fluorimeter | B | 8.12 | pKi | 7.56 | nM | Ki | J Med Chem (2018) 61: 3454-3477 [PMID:29589441] |
| ChEMBL | Inhibition of human full-length recombinant HDAC6 expressed in baculovirus infected Sf9 insect cells using Boc-Lys (Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay | B | 8.46 | pKi | 3.43 | nM | Ki | J Med Chem (2019) 62: 857-874 [PMID:30525585] |
| ChEMBL | Inhibition of human HDAC6 | B | 8.48 | pKi | 3.3 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of full length human HDAC6 using FAM-labeled acetylated peptide as substrate by electrophoretic mobility shift assay | B | 4.82 | pIC50 | 15000 | nM | IC50 | J Med Chem (2021) 64: 2691-2704 [PMID:33576627] |
| ChEMBL | Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay | B | 5.6 | pIC50 | 2500 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of recombinant human HDAC8 using RHKKAc fluorogenic peptide substrate | B | 6.07 | pIC50 | 854 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) after 60 mins by fluorescence assay | B | 6.52 | pIC50 | <300 | nM | IC50 | J Med Chem (2013) 56: 4816-4820 [PMID:23672185] |
| ChEMBL | Inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 90 mins by fluorimetry | B | 6.93 | pIC50 | 118 | nM | IC50 | Eur J Med Chem (2021) 211: 113095-113095 [PMID:33360560] |
| ChEMBL | Inhibition of dye-labeled tracer binding to HDAC6 (unknown origin) transfected in human HeLa cells measured after 2 hrs by nano-luciferase reporter gene-based BRET assay | B | 7 | pIC50 | 100 | nM | IC50 | J Med Chem (2019) 62: 4426-4443 [PMID:30964290] |
| ChEMBL | Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis | B | 7.03 | pIC50 | 94.3 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925] |
| ChEMBL | Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using Z-(Ac)-Lys-AMC as substrate incubated for 40 mins by fluorescence based assay | B | 7.19 | pIC50 | 64.04 | nM | IC50 | Eur J Med Chem (2021) 218: 113392-113392 [PMID:33831778] |
| ChEMBL | Inhibition of human recombinant HDAC6 expressed in baculovirus infected insect cells using BATCP as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis | B | 7.46 | pIC50 | 34.9 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925] |
| ChEMBL | Inhibition of HDAC6 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method | B | 7.51 | pIC50 | 31 | nM | IC50 | Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330] |
| ChEMBL | Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA | B | 7.51 | pIC50 | 31 | nM | IC50 | ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317] |
| ChEMBL | Inhibition of human recombinant N-terminal GST-tagged full length HDAC6 expressed in insect SF9 cells using fluorogenic ZMAL as substrate after 90 mins by fluorescence-based assay | B | 7.52 | pIC50 | 30.4 | nM | IC50 | Eur J Med Chem (2018) 157: 127-138 [PMID:30092367] |
| ChEMBL | Inhibition of full length N-terminal GST-tagged human HDAC6 expressed in baculovirus expression system using ZMAL as substrate incubated for 90 mins by fluorescence assay | B | 7.52 | pIC50 | 30.4 | nM | IC50 | ACS Med Chem Lett (2020) 11: 2268-2276 [PMID:33214839] |
| ChEMBL | Inhibition of recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay | B | 7.52 | pIC50 | 30 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of recombinant human HDAC6 using Fluor de Lys-SIRT1 as substrate incubated for 15 mins by fluorescence assay | B | 7.54 | pIC50 | 28.88 | nM | IC50 | Eur J Med Chem (2016) 116: 126-135 [PMID:27060764] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) using Ac-LeuGlyLy-s(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for 2 hrs by fluorescence microtiter plate reader assay | B | 7.56 | pIC50 | 27.4 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells pretreated with compound followed by Fluor de Lys deacetylase substrate addition by fluorescence method | B | 7.68 | pIC50 | 21 | nM | IC50 | J Med Chem (2019) 62: 10711-10739 [PMID:31710483] |
| ChEMBL | Inhibition of recombinant human HDAC6 using fluorogenic HDAC substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by fluorescence analysis | B | 7.7 | pIC50 | 20 | nM | IC50 | Bioorg Med Chem (2018) 26: 5718-5729 [PMID:30385227] |
| ChEMBL | Inhibition of N-terminal GST-tagged full-length human HDAC6 expressed in Sf9 infected baculovirus system using FTS as substrate preincubated for 10 mins followed by substrate addition and measured for 30 mins | B | 7.72 | pIC50 | 18.9 | nM | IC50 | Eur J Med Chem (2021) 218: 113383-113383 [PMID:33799069] |
| ChEMBL | Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2012) 55: 9891-9899 [PMID:23009203] |
| ChEMBL | Inhibition of human recombinant HDAC6 using RHKKAcAMC as substrate by fluorescence assay | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2018) 152: 329-357 [PMID:29738953] |
| ChEMBL | Inhibition of HADC6 (unknown origin) | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of human HDAC6 using (Z-(Ac)Lys-AMC) as substrate after 90 mins by fluorescence analysis | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2019) 162: 321-333 [PMID:30448419] |
| ChEMBL | Inhibition of recombinant human HDAC6 using RHKKAc as substrate by fluorescence assay | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2015) 58: 7611-7633 [PMID:26086931] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) | B | 7.82 | pIC50 | 15 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 4826-4830 [PMID:25240614] |
| ChEMBL | Inhibition of recombinant human HDAC6 using RHKKAc fluorogenic peptide substrate | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of recombinant N-GST-tagged HDAC6 (unknown origin) assessed as reduction in deacetylation of Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorescence assay | B | 7.82 | pIC50 | 15 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of recombinant human HDAC-6 using RHKKAc as substrate | B | 7.82 | pIC50 | 15 | nM | IC50 | Medchemcomm (2012) 3: 135-161 |
| ChEMBL | Inhibition of human HDAC6 using fluorogenic HDAC substrate | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2018) 158: 620-706 [PMID:30245394] |
| ChEMBL | Inhibition of human HDAC6 using p53 fluorogenic peptide (379 to 382 residues) RHKKAc as substrate by fluorescence-based assay | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2018) 143: 1406-1418 [PMID:29133060] |
| ChEMBL | Inhibition of human recombinant HDAC6 using RHKKAc as substrate | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of human recombinant HDAC6 using RHKKAc peptide as substrate incubated for 5 to mins prior to substrate addition measured after 2 hrs | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2012) 55: 639-651 [PMID:22165909] |
| ChEMBL | Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2013) 56: 6775-6791 [PMID:23905680] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) | B | 7.82 | pIC50 | 15 | nM | IC50 | Bioorg Med Chem Lett (2021) 47: 128204-128204 [PMID:34139324] |
| ChEMBL | Inhibition of human recombinant HDAC6 protein using RHKKAc from p53 as substrate | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of recombiant human HDAC6 using fluorogenic HDAC substrate 3 measured after 30 mins by fluorescence microplate reader assay | B | 7.82 | pIC50 | 15 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Inhibition of human recombinant full-length HDAC6 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2018) 150: 506-524 [PMID:29549837] |
| GtoPdb | - | - | 7.85 | pIC50 | 14 | nM | IC50 | US8748451. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 7.85 | pIC50 | 14 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay | B | 7.85 | pIC50 | 14 | nM | IC50 | Medchemcomm (2019) 10: 1109-1115 [PMID:31391882] |
| ChEMBL | Inhibition of human recombinant HDAC6 using ZMAL (Z-Lys(Ac)-AMC) fluorogenic substrate incubated for 90 mins by fluorescence based assay | B | 7.85 | pIC50 | 14 | nM | IC50 | J Med Chem (2020) 63: 10339-10351 [PMID:32803970] |
| ChEMBL | Inhibition of recombinant human KDAC6 using acetylated p53 (379 to 382 residues) as substrate by fluorescence assay | B | 7.85 | pIC50 | 14 | nM | IC50 | J Med Chem (2016) 59: 1613-1633 [PMID:26681404] |
| ChEMBL | Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 expressed in Sf9 cells using RHKK(Ac) as substrate after 90 mins by fluorimetric method | B | 7.86 | pIC50 | 13.7 | nM | IC50 | Eur J Med Chem (2017) 127: 115-127 [PMID:28038324] |
| ChEMBL | Inhibition of human HDAC6 using fluorogenic-(RHKKAc) as substrate by fluorescence assay | B | 7.86 | pIC50 | 13.7 | nM | IC50 | Bioorg Med Chem (2020) 28: 115250-115250 [PMID:31924504] |
| ChEMBL | Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay | B | 7.89 | pIC50 | 13 | nM | IC50 | Eur J Med Chem (2018) 150: 506-524 [PMID:29549837] |
| ChEMBL | Inhibition of human recombinant HDAC6 using fluorogenic HDAC substrate 3 pre-incubated for 30 mins followed by HDAC developer addition and measured after 15 mins by fluorogenic assay | B | 7.95 | pIC50 | 11.14 | nM | IC50 | Bioorg Med Chem (2019) 27: 3408-3420 [PMID:31235266] |
| ChEMBL | Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate by fluorescence assay | B | 7.96 | pIC50 | 11 | nM | IC50 | J Med Chem (2016) 59: 8233-8262 [PMID:27541357] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) | B | 8.36 | pIC50 | 4.4 | nM | IC50 | J Med Chem (2020) 63: 10246-10262 [PMID:32815366] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 8.4 | pIC50 | 4 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human full length recombinant HDAC6 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 8.4 | pIC50 | 4 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | Inhibition of human HDAC6 using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate | B | 8.46 | pIC50 | 3.5 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 2636-2640 [PMID:29945795] |
| ChEMBL | Inhibition of N-terminal GST tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected insect cells using RHKKAc as substrate in presence of ATP | B | 8.46 | pIC50 | 3.5 | nM | IC50 | J Med Chem (2017) 60: 8336-8357 [PMID:28953386] |
| ChEMBL | Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay | B | 8.46 | pIC50 | 3.5 | nM | IC50 | J Med Chem (2016) 59: 8233-8262 [PMID:27541357] |
| ChEMBL | Inhibition of HDAC6 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 8.7 | pIC50 | 2 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
| ChEMBL | Inhibition of human HDAC6 pre-incubated for 5 mins before substrate addition and measured after 30 mins by fluorescence based assay | B | 8.72 | pIC50 | 1.9 | nM | IC50 | J Med Chem (2021) 64: 1116-1126 [PMID:33356256] |
| ChEMBL | Inhibition of HDAC6 in human RPMI-8226 cells assessed as increase in tubulin acetylation incubated for 6 hrs by Western blot analysis | B | 5.96 | pEC50 | 1090 | nM | EC50 | J Med Chem (2021) 64: 4810-4840 [PMID:33830764] |
| histone deacetylase 6/Histone deacetylase 6 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2878] [GtoPdb: 2618] [UniProtKB: Q9Z2V5] | ||||||||
| ChEMBL | Inhibition of HDAC6 in mouse N2A cells | B | 8.36 | pIC50 | 4.4 | nM | IC50 | ACS Med Chem Lett (2020) 11: 706-712 [PMID:32435374] |
| ChEMBL | Inhibition of HDAC6 in mouse N2A cells assessed as increase in alpha tubulin acetylation | B | 6.84 | pEC50 | 145 | nM | EC50 | ACS Med Chem Lett (2020) 11: 706-712 [PMID:32435374] |
| histone deacetylase 7/Histone deacetylase 7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2716] [GtoPdb: 2661] [UniProtKB: Q8WUI4] | ||||||||
| ChEMBL | Inhibition of HDAC7 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of human recombinant HDAC7 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC7 using acetyl-Lys(trifluoroacetyl)-AMC as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of HDAC7 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of HDAC7 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.01 | pIC50 | 9700 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of HDAC7 (unknown origin) measured after 30 mins by fluorescence microplate reader assay | B | 5.3 | pIC50 | >5000 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | Inhibition of HDAC7 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 6.42 | pIC50 | 379 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
| ChEMBL | Inhibition of human full length recombinant HDAC7 using p53 (379 to 382 residues) Ac-LGK(TFA)-AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 6.51 | pIC50 | 306 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| Histone deacetylase 8 in Schistosoma mansoni (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3797017] [UniProtKB: A5H660] | ||||||||
| ChEMBL | Inhibition of Schistosoma mansoni KDAC8 using (FAM)-labeled peptide as substrate after 60 mins by microfluidic assay | B | 5.83 | pIC50 | 1479.11 | nM | IC50 | Bioorg Med Chem (2017) 25: 2105-2132 [PMID:28259528] |
| histone deacetylase 8/Histone deacetylase 8 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3192] [GtoPdb: 2619] [UniProtKB: Q9BY41] | ||||||||
| ChEMBL | Inhibition of C-terminal His-fusion tagged/N-terminal Strep-2 tagged recombinant human HDAC8 (1 to 377 residues) expressed in insect cells using Boc-Lys(TFa)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins measured after 15 mins by microplate reader based fluorescence assay | B | 4.91 | pKi | 12300 | nM | Ki | Bioorg Med Chem (2019) 27: 115036-115036 [PMID:31431326] |
| ChEMBL | Inhibition of human HDAC8 | B | 7.02 | pKi | 96.2 | nM | Ki | Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120] |
| ChEMBL | Inhibition of recombinant human KDAC8 using diacetylated p53 (379 to 382 residues) as substrate by fluorescence assay | B | 5.63 | pIC50 | 2340 | nM | IC50 | J Med Chem (2016) 59: 1613-1633 [PMID:26681404] |
| ChEMBL | Inhibition of HDAC8 (unknown origin) using Ac-LeuGlyLys(tfa)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for incubated for 1 hrs by fluorescence microtiter plate reader assay | B | 5.72 | pIC50 | 1899 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.9 | pIC50 | 1270 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human recombinant HDAC8 using RHKAcKAc as substrate | B | 6.07 | pIC50 | 854 | nM | IC50 | J Med Chem (2013) 56: 7201-7211 [PMID:23964961] |
| ChEMBL | Inhibition of full length C-terminal 6x-His tagged human HDAC8 using Arg-His-Lys(Ac)-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay | B | 6.07 | pIC50 | 854 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270] |
| ChEMBL | Inhibition of HDAC8 (unknown origin) | B | 6.07 | pIC50 | 854 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 4826-4830 [PMID:25240614] |
| ChEMBL | Inhibition of HDAC8 (unknown origin) measured after 30 mins by fluorescence microplate reader assay | B | 6.07 | pIC50 | 854 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | Inhibition of HDAC8 (unknown origin) | B | 6.07 | pIC50 | 854 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of HADC8 (unknown origin) | B | 6.07 | pIC50 | 854 | nM | IC50 | J Med Chem (2020) 63: 23-39 [PMID:31415174] |
| ChEMBL | Inhibition of HDAC8 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 6.07 | pIC50 | 854 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of human recombinant HDAC8 protein using RHKAcKAc from p53 as substrate | B | 6.07 | pIC50 | 854 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate | B | 6.07 | pIC50 | 854 | nM | IC50 | J Med Chem (2013) 56: 6775-6791 [PMID:23905680] |
| ChEMBL | Inhibition of HDAC8 (unknown origin) | B | 6.07 | pIC50 | 850 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 6.09 | pIC50 | 814 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| GtoPdb | - | - | 6.09 | pIC50 | 814 | nM | IC50 | US8748451. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of human full length recombinant HDAC8 using p53 (379 to 382 residues) (RHK(Ac)K(Ac)AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 6.12 | pIC50 | 755 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | Inhibition of human recombinant HDAC8 expressed in Escherichia coli using Fluor de Lys substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay | B | 6.16 | pIC50 | 695 | nM | IC50 | ACS Med Chem Lett (2020) 11: 2268-2276 [PMID:33214839] |
| ChEMBL | Inhibition of recombinant human HDAC8 expressed in baculovirus expression system using fluorogenic Arg-His-Lys(Ac)-Lys(Ac) as substrate incubated for 90 mins by fluorescence assay | B | 6.16 | pIC50 | 695 | nM | IC50 | J Med Chem (2019) 62: 1138-1166 [PMID:30645113] |
| ChEMBL | Inhibition of HDAC8 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 6.17 | pIC50 | 681 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
| ChEMBL | Inhibition of human recombinant full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 mins by fluorimetric method | B | 6.48 | pIC50 | 330 | nM | IC50 | Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330] |
| ChEMBL | Inhibition of full length human C-terminal His-tag HDAC8 expressed in baculovirus expression system preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA | B | 6.48 | pIC50 | 330 | nM | IC50 | ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317] |
| histone deacetylase 9/Histone deacetylase 9 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4145] [GtoPdb: 2620] [UniProtKB: Q9UKV0] | ||||||||
| ChEMBL | Inhibition of HDAC9 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 141: 596-602 [PMID:29102179] |
| ChEMBL | Inhibition of human recombinant HDAC9 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate | B | 4.52 | pIC50 | >30000 | nM | IC50 | J Med Chem (2013) 56: 6297-6313 [PMID:23627282] |
| ChEMBL | Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014) |
| ChEMBL | Inhibition of HDAC9 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929] |
| ChEMBL | Inhibition of HDAC9 (unknown origin) | B | 4.52 | pIC50 | >30000 | nM | IC50 | Eur J Med Chem (2017) 135: 174-195 [PMID:28453994] |
| ChEMBL | Inhibition of recombinant human HDAC9 measured after 30 mins by fluorescence microplate reader assay | B | 5.3 | pIC50 | >5000 | nM | IC50 | J Med Chem (2021) 64: 15280-15296 [PMID:34624191] |
| ChEMBL | HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. | B | 5.37 | pIC50 | 4310 | nM | IC50 | US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016) |
| ChEMBL | Inhibition of human full length recombinant HDAC9 using p53 (379 to 382 residues) Ac-LGK(TFA)-AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method | B | 6.13 | pIC50 | 739 | nM | IC50 | J Med Chem (2020) 63: 12460-12484 [PMID:32608981] |
| ChEMBL | Inhibition of HDAC9 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay | B | 6.21 | pIC50 | 621 | nM | IC50 | J Med Chem (2013) 56: 1772-1776 [PMID:23368884] |
ChEMBL data shown on this page come from version 33:
Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
